What do systematic reviews say?

Pregabalin vs placebo

• Pregabalin for pain in fibromyalgia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1874 participants
  High

Intervention not reported

• Antipsychotics for fibromyalgia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 155 participants
  Very low

Azathioprine vs budesonide

It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 5.13 [0.25, 103.43]
  1 study · 77 participants
  Very low

Azathioprine + infliximab vs infliximab

It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 2.42 [0.1, 56.46]
  1 study · 45 participants
  Very low

6‐Mercaptopurine vs methotrexate

It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 0.68 [0.17, 2.75]
  1 study · 57 participants
  Very low

Azathioprine or 6‐mercaptopurine vs placebo

It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with placebo (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 3.12 [1.59, 6.09]
  7 studies · 661 participants
  Very low

Azathioprine or 6‐mercaptopurine vs mesalazine or sulfasalazine

It is very uncertain whether azathioprine or 6‐mercaptopurine changes withdrawals due to adverse events compared with mesalazine or sulfasalazine (very low certainty).

• Azathioprine or 6‐mercaptopurine for maintenance of remission in Crohn's disease 2015 · Cochrane Headline outcomes only
  RR 1.86 [0.87, 3.97]
  2 studies · 290 participants
  Very low

Intervention not reported

The review found no eligible studies for this question.

• TNF‐alpha inhibitors for ankylosing spondylitis 2015 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Chondroitin vs placebo

Chondroitin showed no clear difference in withdrawals due to adverse events compared with placebo (moderate certainty).

• Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
  RR 1.08 [0.74, 1.57]
  10 studies · 2406 participants
  Moderate

Type I Interferons vs placebo

Type I Interferons may leads to higher withdrawals due to adverse events compared with placebo (low certainty).

• Type I interferons for induction of remission in ulcerative colitis 2015 · Cochrane Headline outcomes only
  RR 3.16 [1.06, 9.4]
  4 studies · 394 participants
  Low

Intervention not reported

• Alprazolam for essential tremor 2015 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 24 participants
  Very low

COX‐2 NSAIDs vs placebo

COX‐2 NSAIDs showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).

• Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… 2015 · Cochrane Headline outcomes only
  RR 2.14 [0.36, 12.56]
  669 participants
  Low

SSRIs or SNRIs vs other antidepressants

SSRIs or SNRIs showed no clear difference in withdrawals due to adverse events compared with other antidepressants (low certainty).

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  OR 1.04 [0.41, 2.6]
  4 studies · 257 participants
  Low

SSRIs or SNRIs vs placebo

It is very uncertain whether SSRIs or SNRIs changes withdrawals due to adverse events compared with placebo (very low certainty).

• Selective serotonin reuptake inhibitors (SSRIs) and serotonin‐norepinephrine reuptake inhibitors (SNRIs) for the… 2015 · Cochrane Headline outcomes only
  OR 3.72 [0.79, 17.53]
  3 studies · 190 participants
  Very low

Deep transverse massage + physical therapy vs physical therapy alone

The review found no eligible studies for this question.

• Deep transverse friction massage for treating lateral elbow or lateral knee tendinitis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Erythropoietin (subcutaneous or intravenous at varying dosages) vs placebo

The review found no eligible studies for this question.

• Erythropoiesis‐stimulating agents for anemia in rheumatoid arthritis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).

• Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
  RR 1.02 [0.1, 10.77]
  1 study · 89 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in withdrawals due to adverse events (moderate certainty).

• Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
  RR 0.75 [0.57, 1]
  4 studies · 1241 participants
  Moderate

Tocilizumab 8 mg/kg + MTX/DMARD vs placebo + DMARDs/biologic

Tocilizumab 8 mg/kg + MTX/DMARD showed no clear difference in withdrawals due to Adverse events compared with placebo + MTX/DMARD (high certainty).

• Tocilizumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
  RR 1.43 [0.95, 2.12]
  4 studies · 2064 participants
  High

Golimumab 50 mg every 4 weeks + MTX vs placebo + MTX

Golimumab 50 mg every 4 weeks + MTX showed no clear difference in withdrawals due to Adverse Events compared with placebo + MTX (high certainty).

• Golimumab for rheumatoid arthritis 2010 · Cochrane Headline outcomes only
  RR 0.56 [0.24, 1.29]
  3 studies · 599 participants
  High